This company listing is no longer active
AVEO Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Key information
-2.9%
Earnings growth rate
32.7%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 51.0% |
Return on equity | -100.7% |
Net Margin | -30.8% |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How AVEO Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 94 | -29 | 68 | 13 |
30 Jun 22 | 79 | -36 | 65 | 10 |
31 Mar 22 | 61 | -41 | 63 | 5 |
31 Dec 21 | 42 | -53 | 61 | 0 |
30 Sep 21 | 26 | -58 | 54 | 20 |
30 Jun 21 | 14 | -56 | 45 | 13 |
31 Mar 21 | 7 | -49 | 34 | 5 |
31 Dec 20 | 6 | -36 | 22 | 0 |
30 Sep 20 | 6 | -29 | 16 | 0 |
30 Jun 20 | 28 | -4 | 13 | 0 |
31 Mar 20 | 28 | 0 | 12 | 0 |
31 Dec 19 | 29 | 9 | 11 | 0 |
30 Sep 19 | 30 | 36 | 11 | 0 |
30 Jun 19 | 6 | -3 | 11 | 0 |
31 Mar 19 | 6 | 4 | 11 | 0 |
31 Dec 18 | 5 | -5 | 11 | 0 |
30 Sep 18 | 4 | -24 | 11 | 0 |
30 Jun 18 | 6 | -28 | 10 | 0 |
31 Mar 18 | 6 | -65 | 9 | 0 |
31 Dec 17 | 8 | -65 | 9 | 0 |
30 Sep 17 | 8 | -74 | 9 | 0 |
30 Jun 17 | 4 | -53 | 9 | 0 |
31 Mar 17 | 4 | -28 | 8 | 0 |
31 Dec 16 | 3 | -27 | 8 | 0 |
30 Sep 16 | 6 | -28 | 10 | 0 |
30 Jun 16 | 20 | -15 | 10 | 0 |
31 Mar 16 | 20 | -12 | 11 | 0 |
Quality Earnings: VPA1 is currently unprofitable.
Growing Profit Margin: VPA1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VPA1 is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare VPA1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VPA1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.1%).
Return on Equity
High ROE: VPA1 has a negative Return on Equity (-100.67%), as it is currently unprofitable.